Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10482405 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2ACELMNAABCB11MMP8 | |
| SCHEMBL14265369 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2ACELMNAABCB11MMP8 | |
| Hydrochloric Acid SCHEMBL11206033 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2ACELMNAABCB11MMP8 | |
| SCHEMBL8530712 | 0.85 | ITGA4 (0.52) | SMN1; SMN2TDP1MAPTTSHR | |
| SCHEMBL13853980 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2ACELMNAABCB11MMP8 | |
| SCHEMBL14385198 | 0.83 | MME (0.55) | ACETSHR | |
| SCHEMBL13016712 | 0.82 | L3MBTL1 (0.52) | SMN1; SMN2ACELMNAABCB11AGTR2 | |
| SCHEMBL10889835 | 0.81 | MMP3 (0.49) | SMN1; SMN2ACELMNAABCB11MMP8 | |
| SCHEMBL12304830 | 0.81 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11PDE3A | |
| SCHEMBL14374305 | 0.81 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | SMN1; SMN2 3985/4885ACE 92/4885LMNA 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.